# Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

> **NCT03548415** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** IONIS-GHR-LRx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03548415
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-13
- **Primary completion:** 2021-02-18
- **Final completion:** 2021-04-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548415, "Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03548415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*